Bay Street News

RedHill Biopharma Provides Full-Year 2019 Financial Results and Operational Highlights

Key Highlights:
Talicia® approved by the FDA for the treatment of H. pylori infection in adults; U.S. launch with RedHill’s sales force expected by mid-March 2020
 
Acquisition of global rights to Movantik® (naloxegol) for the treatment of opioid-induced constipation (OIC) in adults from AstraZeneca, subject to certain closing conditions and regulatory clearances; Movantik® generated U.S. net sales of $96 million in 2019
 

Bay Street News